Skip to contentB
Benitec Biopharma Inc.
B
BNTCBenitec Biopharma Inc. Q2 2024 · 10-Q
Revenue$0.00$0.00−100.0% vs Q2 2023 Net Income-$6.80M-$6.80MN/M vs Q2 2023 EPS Diluted-$2.64-$2.64N/M vs Q2 2023 Operating Income-$6,927,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Benitec Biopharma Inc. · CIK 1808898 · Engraved from SEC EDGAR
derived
ended Dec 31, 2023 · filed Feb 13, 2024 · 44 d after period end